GE Healthcare Technologies Inc. (GEHC) stock soared 5.12% in the pre-market session on Thursday, following the company's strong fourth quarter 2024 earnings results.

The medical technology company reported adjusted earnings per share of $1.45 for Q4, surpassing analyst estimates of $1.26. Revenue grew 2% year-over-year to $5.32 billion, narrowly missing expectations of $5.33 billion.

GE Healthcare saw double-digit revenue growth in its Pharmaceutical Diagnostics and Advanced Visualization Solutions segments. The company highlighted robust momentum in orders, backlog levels, and book-to-bill ratios during the quarter.

For the full year 2025, GE Healthcare provided upbeat adjusted EPS guidance of $4.61 to $4.75, higher than the consensus estimate of $4.66. The company cited continued strong demand for its products and services, although it expects some headwinds in China due to a delay in stimulus measures and an ongoing anti-corruption campaign.

Investors cheered GE Healthcare's better-than-expected profit performance and optimistic outlook, driving the stock's pre-market rally. The company's solid execution and growth prospects in key healthcare segments appear to be fueling the stock's momentum.